Compound Detail
CHEMBL4650393
EPCORITAMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4650393 |
| Name | EPCORITAMAB |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
6
Known Names
8
Indications
2
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2023 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| B-lymphocyte antigen CD20 binding agent | BINDING AGENT | B-lymphocyte antigen CD20 | ✓ | ✓ |
| T cell surface glycoprotein CD3 binding agent | BINDING AGENT | T cell surface glycoprotein CD3 | ✓ | ✓ |
Indications
Lymphoma, Follicular Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse Neoplasms Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, B-Cell Lymphoma, Mantle-Cell
ATC Classification
L01FX27
epcoritamab
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Drug Warnings
Black Box Warning
immune system toxicity
Data from ChEMBL 36 via Core Engine